- Home
- IGMS vs MESO Comparison
IGMS vs MESO Comparison
Compare IGMS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- MESO
- Stock Information
- Founded
- IGMS 1993
- MESO 2004
- Country
- IGMS United States
- MESO Australia
- Employees
- IGMS N/A
- MESO N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGMS Health Care
- MESO Health Care
- Exchange
- IGMS Nasdaq
- MESO Nasdaq
- Market Cap
- IGMS 962.1M
- MESO 1.1B
- IPO Year
- IGMS 2019
- MESO N/A
- Fundamental
- Price
- IGMS $9.47
- MESO $10.04
- Analyst Decision
- IGMS Hold
- MESO Strong Buy
- Analyst Count
- IGMS 8
- MESO 4
- Target Price
- IGMS $14.63
- MESO $11.50
- AVG Volume (30 Days)
- IGMS 238.9K
- MESO 204.9K
- Earning Date
- IGMS 11-08-2024
- MESO 08-28-2024
- Dividend Yield
- IGMS N/A
- MESO N/A
- EPS Growth
- IGMS N/A
- MESO N/A
- EPS
- IGMS N/A
- MESO N/A
- Revenue
- IGMS $2,918,000.00
- MESO $5,902,000.00
- Revenue This Year
- IGMS $298.54
- MESO $66.05
- Revenue Next Year
- IGMS N/A
- MESO $348.27
- P/E Ratio
- IGMS N/A
- MESO N/A
- Revenue Growth
- IGMS 57.64
- MESO N/A
- 52 Week Low
- IGMS $4.72
- MESO $1.61
- 52 Week High
- IGMS $22.50
- MESO $12.18
- Technical
- Relative Strength Index (RSI)
- IGMS 28.30
- MESO 55.85
- Support Level
- IGMS $10.91
- MESO $8.52
- Resistance Level
- IGMS $16.32
- MESO $12.18
- Average True Range (ATR)
- IGMS 1.53
- MESO 0.63
- MACD
- IGMS -0.79
- MESO 0.17
- Stochastic Oscillator
- IGMS 0.80
- MESO 57.96
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.